I-Mab ADR (IMAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMAB Stock Price Chart Interactive Chart >
IMAB Price/Volume Stats
|Current price||$11.49||52-week high||$84.05|
|Prev. close||$11.30||52-week low||$8.05|
|Day high||$11.82||Avg. volume||1,125,314|
|50-day MA||$11.19||Dividend yield||N/A|
|200-day MA||$34.86||Market Cap||949.60M|
I-Mab ADR (IMAB) Company Bio
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Most Popular Stories View All
IMAB Latest News Stream
|Loading, please wait...|
IMAB Latest Social Stream
View Full IMAB Social Stream
Latest IMAB News From Around the Web
Below are the latest news stories about I-Mab that investors may wish to consider to help them evaluate IMAB as an investment opportunity.
In the last trading session, 1.25 million shares of the I-Mab (NASDAQ:IMAB) were traded. Most recently the company’s share price was $27.82, and it changed around $2.93 or 11.77% from the last close, which brings the market valuation of the company to $2.36B. IMAB currently trades at a discount to its 52-week high of $85.40, … Why I-Mab (NASDAQ: IMAB) Stock Should Not Be Discarded By Investors In 2022 Read More »
I-Mab (NASDAQ:IMAB)s traded shares stood at 0.59 million during the last session. At the close of trading, the stocks price was $23.63, to imply a decrease of -5.67% or -$1.42 in intraday trading. The IMAB shares 52-week high remains $85.40, putting it -261.4% down since that peak but still an impressive 14.52% since price per After Sinking 4.33% During Past Week, Is I-Mab (NASDAQ: IMAB) Still A Buy? Read More »
Investment company Strategic Vision Investment Ltd (Current Portfolio) buys Amazon.com Inc, Qualtrics International Inc, I-MAB, DiDi Global Inc, ACM Research Inc, sells Sea, Kanzhun, Stem Inc, New Frontier Health Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Strategic Vision Investment Ltd.
No summary available.
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization. This strategic partnership will accelerate I-Mab's commercialization strategy with an execution plan and timeline to commercialize its innovative
IMAB Price Returns